Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox

Florian Nolte; Emanuele Angelucci; Photis Beris; Alan Macwhannell; Dominik Selleslag; Christiane Schumann; Blanca Xicoy; António Almeida; Agnés Guerci-Bresler; Thamer Sliwa; Petra Muus; John Porter; Wolf K. Hofmann

doi:10.1016/j.leukres.2011.06.013

Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox

Florian Nolte^*, Emanuele Angelucci, Photis Beris, Alan Macwhannell, Dominik Selleslag, Christiane Schumann, Blanca Xicoy, António Almeida, Agnés Guerci-Bresler, Thamer Sliwa, Petra Muus, John Porter, Wolf K. Hofmann

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Myelodysplastic syndromes are characterized by ineffective hematopoiesis resulting in peripheral cytopenias. The majority of patients is dependent on regular transfusions of packed red blood cells leading to a secondary iron overload which might result in organ damage. Therefore, sufficient iron chelation therapy in selected patients is mandatory. Deferasirox (DFX) is an orally administered iron chelator which has been highly efficient in the treatment of secondary iron overload. Most frequent side effects of DFX are gastrointestinal disturbances, which leads in some patients to low adherence to the therapy. An expert panel met in Lisbon in July 2010 to develop recommendations on prevention and management of GI disturbances based on existing data and personal experiences.

Original language	English
Pages (from-to)	1131-1135
Number of pages	5
Journal	Leukemia Research
Volume	35
Issue number	9
DOIs	https://doi.org/10.1016/j.leukres.2011.06.013
Publication status	Published - Sept 2011
Externally published	Yes

Keywords

Chelation
Deferasirox
Gastrointestinal disturbances
Iron overload
Myelodysplastic syndrome
Transfusion

Access to Document

10.1016/j.leukres.2011.06.013

Cite this

Nolte, F., Angelucci, E., Beris, P., Macwhannell, A., Selleslag, D., Schumann, C., Xicoy, B., Almeida, A., Guerci-Bresler, A., Sliwa, T., Muus, P., Porter, J., & Hofmann, W. K. (2011). Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. Leukemia Research, 35(9), 1131-1135. https://doi.org/10.1016/j.leukres.2011.06.013

@article{c90eecf3f2ed4cd68786293703080e34,

title = "Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox",

abstract = "Myelodysplastic syndromes are characterized by ineffective hematopoiesis resulting in peripheral cytopenias. The majority of patients is dependent on regular transfusions of packed red blood cells leading to a secondary iron overload which might result in organ damage. Therefore, sufficient iron chelation therapy in selected patients is mandatory. Deferasirox (DFX) is an orally administered iron chelator which has been highly efficient in the treatment of secondary iron overload. Most frequent side effects of DFX are gastrointestinal disturbances, which leads in some patients to low adherence to the therapy. An expert panel met in Lisbon in July 2010 to develop recommendations on prevention and management of GI disturbances based on existing data and personal experiences.",

keywords = "Chelation, Deferasirox, Gastrointestinal disturbances, Iron overload, Myelodysplastic syndrome, Transfusion",

author = "Florian Nolte and Emanuele Angelucci and Photis Beris and Alan Macwhannell and Dominik Selleslag and Christiane Schumann and Blanca Xicoy and Ant{\'o}nio Almeida and Agn{\'e}s Guerci-Bresler and Thamer Sliwa and Petra Muus and John Porter and Hofmann, {Wolf K.}",

year = "2011",

month = sep,

doi = "10.1016/j.leukres.2011.06.013",

language = "English",

volume = "35",

pages = "1131--1135",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "9",

}

Nolte, F, Angelucci, E, Beris, P, Macwhannell, A, Selleslag, D, Schumann, C, Xicoy, B, Almeida, A, Guerci-Bresler, A, Sliwa, T, Muus, P, Porter, J & Hofmann, WK 2011, 'Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox', Leukemia Research, vol. 35, no. 9, pp. 1131-1135. https://doi.org/10.1016/j.leukres.2011.06.013

TY - JOUR

T1 - Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox

AU - Nolte, Florian

AU - Angelucci, Emanuele

AU - Beris, Photis

AU - Macwhannell, Alan

AU - Selleslag, Dominik

AU - Schumann, Christiane

AU - Xicoy, Blanca

AU - Almeida, António

AU - Guerci-Bresler, Agnés

AU - Sliwa, Thamer

AU - Muus, Petra

AU - Porter, John

AU - Hofmann, Wolf K.

PY - 2011/9

Y1 - 2011/9

N2 - Myelodysplastic syndromes are characterized by ineffective hematopoiesis resulting in peripheral cytopenias. The majority of patients is dependent on regular transfusions of packed red blood cells leading to a secondary iron overload which might result in organ damage. Therefore, sufficient iron chelation therapy in selected patients is mandatory. Deferasirox (DFX) is an orally administered iron chelator which has been highly efficient in the treatment of secondary iron overload. Most frequent side effects of DFX are gastrointestinal disturbances, which leads in some patients to low adherence to the therapy. An expert panel met in Lisbon in July 2010 to develop recommendations on prevention and management of GI disturbances based on existing data and personal experiences.

AB - Myelodysplastic syndromes are characterized by ineffective hematopoiesis resulting in peripheral cytopenias. The majority of patients is dependent on regular transfusions of packed red blood cells leading to a secondary iron overload which might result in organ damage. Therefore, sufficient iron chelation therapy in selected patients is mandatory. Deferasirox (DFX) is an orally administered iron chelator which has been highly efficient in the treatment of secondary iron overload. Most frequent side effects of DFX are gastrointestinal disturbances, which leads in some patients to low adherence to the therapy. An expert panel met in Lisbon in July 2010 to develop recommendations on prevention and management of GI disturbances based on existing data and personal experiences.

KW - Chelation

KW - Deferasirox

KW - Gastrointestinal disturbances

KW - Iron overload

KW - Myelodysplastic syndrome

KW - Transfusion

UR - http://www.scopus.com/inward/record.url?scp=80051475539&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.06.013

DO - 10.1016/j.leukres.2011.06.013

M3 - Article

C2 - 21737138

AN - SCOPUS:80051475539

SN - 0145-2126

VL - 35

SP - 1131

EP - 1135

JO - Leukemia Research

JF - Leukemia Research

IS - 9

ER -

Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this